501 related articles for article (PubMed ID: 25503183)
1. Mesothelin in serum and pleural effusion in the diagnosis of malignant pleural mesothelioma with non-positive cytology.
Franceschini MC; Ferro P; Canessa PA; Battolla E; Dessanti P; Valentino A; Casolari L; Fontana V; Pezzi R; Fedeli F; Pistillo MP; Roncella S
Anticancer Res; 2014 Dec; 34(12):7425-9. PubMed ID: 25503183
[TBL] [Abstract][Full Text] [Related]
2. Mesothelin is more useful in pleural effusion than in serum in the diagnosis of pleural mesothelioma.
Ferro P; Canessa PA; Battolla E; Dessanti P; Franceschini MC; Chiaffi L; Morabito A; Fontana V; Pezzi R; Fedeli F; Pistillo MP; Roncella S
Anticancer Res; 2013 Jun; 33(6):2707-13. PubMed ID: 23749930
[TBL] [Abstract][Full Text] [Related]
3. Combination of mesothelin and CEA significantly improves the differentiation between malignant pleural mesothelioma, benign asbestos disease, and lung cancer.
Muley T; Dienemann H; Herth FJ; Thomas M; Meister M; Schneider J
J Thorac Oncol; 2013 Jul; 8(7):947-51. PubMed ID: 23777840
[TBL] [Abstract][Full Text] [Related]
4. Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions.
Pass HI; Wali A; Tang N; Ivanova A; Ivanov S; Harbut M; Carbone M; Allard J
Ann Thorac Surg; 2008 Jan; 85(1):265-72; discussion 272. PubMed ID: 18154821
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer.
Schneider J; Hoffmann H; Dienemann H; Herth FJ; Meister M; Muley T
J Thorac Oncol; 2008 Nov; 3(11):1317-24. PubMed ID: 18978568
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of soluble mesothelin-related peptide as a diagnostic marker of malignant pleural mesothelioma effusions: its contribution to cytology.
Canessa PA; Franceschini MC; Ferro P; Battolla E; Dessanti P; Manta C; Sivori M; Pezzi R; Fontana V; Fedeli F; Pistillo MP; Roncella S
Cancer Invest; 2013 Jan; 31(1):43-50. PubMed ID: 23249166
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of pleural effusion mesothelin in malignant pleural mesothelioma.
Yamada S; Tabata C; Tabata R; Fukuoka K; Nakano T
Clin Chem Lab Med; 2011 Oct; 49(10):1721-6. PubMed ID: 21692685
[TBL] [Abstract][Full Text] [Related]
8. Soluble Mesothelin-Related Peptides to Monitor Recurrence After Resection of Pleural Mesothelioma.
Burt BM; Lee HS; Lenge De Rosen V; Hamaji M; Groth SS; Wheeler TM; Sugarbaker DJ
Ann Thorac Surg; 2017 Nov; 104(5):1679-1687. PubMed ID: 28964420
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of New Biomarkers in the Prediction of Malignant Mesothelioma in Subjects with Environmental Asbestos Exposure.
Demir M; Kaya H; Taylan M; Ekinci A; Yılmaz S; Teke F; Sezgi C; Tanrikulu AC; Meteroglu F; Senyigit A
Lung; 2016 Jun; 194(3):409-17. PubMed ID: 27032653
[TBL] [Abstract][Full Text] [Related]
10. Pleural effusion biomarkers and computed tomography findings in diagnosing malignant pleural mesothelioma: A retrospective study in a single center.
Otoshi T; Kataoka Y; Ikegaki S; Saito E; Matsumoto H; Kaku S; Shimada M; Hirabayashi M
PLoS One; 2017; 12(10):e0185850. PubMed ID: 28968445
[TBL] [Abstract][Full Text] [Related]
11. Glycodelin is a potential novel follow-up biomarker for malignant pleural mesothelioma.
Schneider MA; Muley T; Kahn NC; Warth A; Thomas M; Herth FJ; Dienemann H; Meister M
Oncotarget; 2016 Nov; 7(44):71285-71297. PubMed ID: 27713145
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the Diagnostic Performance of Fibulin-3 and Mesothelin in Patients with Pleural Effusions from Malignant Mesothelioma.
Battolla E; Canessa PA; Ferro P; Franceschini MC; Fontana V; Dessanti P; Pinelli V; Morabito A; Fedeli F; Pistillo MP; Roncella S
Anticancer Res; 2017 Mar; 37(3):1387-1391. PubMed ID: 28314308
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic value of soluble mesothelin-related peptides in pleural effusion for malignant pleural mesothelioma: An updated meta-analysis.
Gao R; Wang F; Wang Z; Wu Y; Xu L; Qin Y; Shi H; Tong Z
Medicine (Baltimore); 2019 Apr; 98(14):e14979. PubMed ID: 30946324
[TBL] [Abstract][Full Text] [Related]
14. Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma.
Scherpereel A; Grigoriu B; Conti M; Gey T; Grégoire M; Copin MC; Devos P; Chahine B; Porte H; Lassalle P
Am J Respir Crit Care Med; 2006 May; 173(10):1155-60. PubMed ID: 16456138
[TBL] [Abstract][Full Text] [Related]
15. Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: relation with past asbestos exposure.
Rodríguez Portal JA; Rodríguez Becerra E; Rodríguez Rodríguez D; Alfageme Michavila I; Quero Martínez A; Diego Roza C; León Jiménez A; Isidro Montes I; Cebollero Rivas P
Cancer Epidemiol Biomarkers Prev; 2009 Feb; 18(2):646-50. PubMed ID: 19190155
[TBL] [Abstract][Full Text] [Related]
16. The relationship between tumor MSLN methylation and serum mesothelin (SMRP) in mesothelioma.
Nelson HH; Almquist LM; LaRocca JL; Plaza SL; Lambert-Messerlian GM; Sugarbaker DJ; Bueno R; Godleski JJ; Marsit CJ; Christensen BC; Kelsey KT
Epigenetics; 2011 Aug; 6(8):1029-34. PubMed ID: 21775819
[TBL] [Abstract][Full Text] [Related]
17. Determination of Mesothelin Levels in Pleural Effusion Does Not Help Predict Survival of Patients With Malignant Pleural Mesothelioma.
Fontana V; Pistillo MP; Vigani A; Canessa PA; Berisso G; Giannoni U; Ferro P; Franceschini MC; Carosio R; Tonarelli M; Rossi C; Dessanti P; Roncella S
Anticancer Res; 2019 Sep; 39(9):5219-5223. PubMed ID: 31519636
[TBL] [Abstract][Full Text] [Related]
18. Combined serum mesothelin and plasma osteopontin measurements in malignant pleural mesothelioma.
Cristaudo A; Bonotti A; Simonini S; Vivaldi A; Guglielmi G; Ambrosino N; Chella A; Lucchi M; Mussi A; Foddis R
J Thorac Oncol; 2011 Sep; 6(9):1587-93. PubMed ID: 21642872
[TBL] [Abstract][Full Text] [Related]
19. Serum mesothelin, osteopontin and vimentin: useful markers for clinical monitoring of malignant pleural mesothelioma.
Bonotti A; Simonini S; Pantani E; Giusti L; Donadio E; Mazzoni MR; Chella A; Marconi L; Ambrosino N; Lucchi M; Mussi A; Cristaudo A; Foddis R
Int J Biol Markers; 2017 Mar; 32(1):e126-e131. PubMed ID: 27646775
[TBL] [Abstract][Full Text] [Related]
20. Significance of serum mesothelin in an asbestos-exposed population in the Czech Republic.
Jakubec P; Pelclova D; Smolkova P; Kolek V; Nakladalova M
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2015 Sep; 159(3):472-9. PubMed ID: 24781044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
